Literature DB >> 10752892

Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis.

K Yutani1, E Shiba, H Kusuoka, M Tatsumi, T Uehara, T Taguchi, S I Takai, T Nishimura.   

Abstract

PURPOSE: The purpose of this work was to compare [18F]2-deoxy-2-fluoro-D-glucose (FDG) PET and 99mTc-methoxyisobutylisonitrile (MIBI) SPECT in the detection of breast cancer and axillary lymph node metastasis in the same patients.
METHOD: FDG-PET and MIBI-SPECT were performed within 3 days for 40 women (age range 25-86 years old) with suspected breast cancer, in whom biopsies and/or mastectomies were performed. Both images were visually assessed, and the count ratio between tumor and normal tissue (T/N ratio) was calculated.
RESULTS: Thirty-eight patients had breast cancer, and the remaining two had benign breast lesions. The sensitivities of FDG-PET and MIBI-SPECT were 78.9 and 76.3% for breast cancer and 50.0 and 37.5% for axillary lymph node metastasis, respectively. The T/N ratio of breast cancer was significantly higher in FDG-PET (6.01 +/- 3.08 mean +/- SD) than that in MIBI-SPECT (3.48 +/- 1.21) (p = 0.01). Nonmalignant diffuse uptake of FDG in the breasts and the accumulation of MIBI in heart and liver occasionally obscured tumor uptake.
CONCLUSION: These results indicate that MIBI-SPECT is comparable with FDG-PET in detecting breast cancer. Neither FDG-PET nor MIBI-SPECT is sufficiently sensitive to rule out axillary lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10752892     DOI: 10.1097/00004728-200003000-00017

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  14 in total

1.  Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?

Authors:  Selin Carkaci; Beatriz E Adrada; Eric Rohren; Wei Wei; Mohammad A Quraishi; Osama Mawlawi; Thomas A Buchholz; Wei Yang
Journal:  Acad Radiol       Date:  2012-02-01       Impact factor: 3.173

2.  Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer.

Authors:  Jacobus J M van der Hoeven; Otto S Hoekstra; Emile F I Comans; Rik Pijpers; Robert P A Boom; Dick van Geldere; Sybren Meijer; Adriaan A Lammertsma; Gerrit J J Teule
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

3.  Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells.

Authors:  Michael Guppy; Peter Leedman; XinLin Zu; Victoria Russell
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

Review 4.  Breast cancer imaging: a perspective for the next decade.

Authors:  Andrew Karellas; Srinivasan Vedantham
Journal:  Med Phys       Date:  2008-11       Impact factor: 4.071

Review 5.  Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients.

Authors:  Giuseppe Madeddu; Angela Spanu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

6.  Regulation of the Warburg effect in early-passage breast cancer cells.

Authors:  Ian F Robey; Renu M Stephen; Kathy S Brown; Brenda K Baggett; Robert A Gatenby; Robert J Gillies
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

Review 7.  A systematic review of FDG-PET in breast cancer.

Authors:  S Escalona; J A Blasco; M M Reza; E Andradas; N Gómez
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

Review 8.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.

Authors:  K Scheidhauer; C Walter; M D Seemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

9.  99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; George A Kastis; Michel Bettan; Lars R Furenlid; Donald W Wilson; James M Woolfenden; Koon Yan Pak
Journal:  Nucl Med Commun       Date:  2004-07       Impact factor: 1.690

10.  Optical imaging in breast cancer diagnosis: the next evolution.

Authors:  Michel Herranz; Alvaro Ruibal
Journal:  J Oncol       Date:  2012-12-04       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.